In forensic toxicology, understanding what is in a sample and how much of it is there, quickly, accurately, and confidently, can make all the difference. Whether it is an overdose investigation, a sudden death case, or surveillance for emerging public health risks, laboratories are under pressure to deliver high-quality results with tighter turnaround times and broader analytical scope.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_Sharper_Faster_Smarter_HRAM_Orbitrap_Mass_Spectrometry_Meets_Postmortem_Toxicology_0ea871cfc2.jpg" alt="Thermo Fisher Scientific - Sharper, Faster, Smarter - HRAM Orbitrap Mass Spectrometry Meets Postmortem Toxicology" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_Sharper_Faster_Smarter_HRAM_Orbitrap_Mass_Spectrometry_Meets_Postmortem_Toxicology_0ea871cfc2.jpg 245w," sizes="100vw" width="1024" height="512">That is where high-resolution, accurate-mass (HRAM) <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?category=134&amp;manufacturerItems=3">Orbitrap mass spectrometry</a> really shines, especially when paired with streamlined workflows and intelligent data analysis.<h3>What’s new?</h3>A recent <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/tn_002551_cl_phsa_orbitrap_forensic_tn002551_na_en_a34276b79b.pdf">Technical Note (TN-002551) </a>details a rapid LC-HRAM-Orbitrap method developed collaboratively with the B.C. Provincial Toxicology Centre for postmortem blood analysis. This workflow was designed to deliver routine screening and quantitation while also enabling retrospective data mining to identify unknown or emerging compounds in circulation.Here is what makes this approach compelling:<ul><li>High sensitivity and resolution: The Thermo Scientific Q Exactive HF hybrid quadrupole-Orbitrap system enables faster scan speeds and precise mass measurement, which boosts confidence in detecting drugs, even at low levels, in complex postmortem matrices.</li><li>Robust routine productivity: Running routine screens in approximately 12.5 minutes significantly speeds workflow throughput, which is critical as labs face growing caseloads.</li><li>Retrospective analysis: One of the biggest advantages of HRAM data is the ability to re-interrogate stored data files for novel psychoactive substances after the initial screen is complete. This capability eliminates the need to re-run samples, saving time and preserving limited sample material.</li></ul>A standout example from the technical note was the identification of bromazolam, a designer benzodiazepine that was not part of the original routine panel. Through retrospective analysis, its prevalence in postmortem cases was revealed and quantified, demonstrating the real-world value of full-scan HRAM data.<h5>Supporting broad drug panels</h5>As highlighted in a previous THC tips and tricks blog post, cannabinoids and their metabolites can be challenging when analyzed alongside other drugs of abuse. HRAM MS improves selectivity and confidence when multiple drug classes are analyzed together, making it easier to integrate THC and related compounds into comprehensive toxicology workflows.<h5>Why this matters for forensic toxicology today</h5>The opioid crisis, the continued emergence of novel psychoactive substances, and evolving public health threats demand analytical tools that are both robust and adaptable. HRAM Orbitrap LC-MS not only improves detection and quantitation across a wide range of drugs of abuse, but also enables:<ul><li>Retrospective discovery of unknown compounds</li><li>Faster delivery of actionable results to coroners and public health agencies</li><li>Improved surveillance of emerging drug trends</li></ul>As toxicology laboratories look to future-proof their operations, combining powerful instrumentation, intelligent software, and optimized workflows will be key. Methods like those described in TN-002551 demonstrate how HRAM Orbitrap mass spectrometry continues to elevate forensic toxicology workflows.<h3>Resources</h3><ul><li>Featured technical note: <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/tn_002551_cl_phsa_orbitrap_forensic_tn002551_na_en_a34276b79b.pdf">Rapid, high-resolution postmortem toxicology analysis using Orbitrap mass spectrometry</a></li><li>Previous blogs in this series:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/6189">Sample Preparation Strategies for Toxicology Workflows</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/6587">Beyond Blood: HRAM-Powered Postmortem Toxicology at Sheffield Teaching Hospitals</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/6860">Advancing Drug Analysis with VeriSpray PaperSpray Mass Spectrometry</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/6953">Boosting Productivity in Toxicology Labs</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/7190">Behind the Bench: Tips to Simultaneously Analyze THC, Its Metabolites, and Other Drugs of Abuse</a></li></ul></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.thermofisher.com/content/lifetech/global/en/home/industrial/forensics/forensic-toxicology.html">Forensic toxicology webpage</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.thermofisher.com/content/lifetech/global/en/home/industrial/mass-spectrometry/mass-spectrometer-price-affordability-programs.html">Affordability resources</a></li></ul><blockquote>Visit us on&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.linkedin.com/showcase/72003132/admin/dashboard/">LinkedIn:</a>&nbsp;#PostmortemAnalysis #HRAMOrbitrapMS #ForensicToxicology #NPS</blockquote>

Sharper, Faster, Smarter: HRAM Orbitrap Mass Spectrometry Meets Postmortem Toxicology

A laboratory will occasionally have a poor performance in a PT scheme. When this occurs, the laboratory should acknowledge it, carry out an investigation and document a review of possible causes, even if it decides not to take any specific action. The purpose of this leaflet is to advise laboratories on how to best address such events. A good management of the poor performance in a PT can save you time and money.&nbsp;<h4>Evaluation of poor performance&nbsp;</h4>Every unsatisfactory performance score indicates a problem which needs to be investigated. In addition the laboratory should set its own criteria for launching an investigation with regards to other indicators of possible poor performance, such as questionable performance scores or observed trends.<h4>Root cause investigation&nbsp;</h4>The depth of the investigation will depend on several factors, such as the importance of the analysis, the frequency of unsatisfactory results and evidence of trends.&nbsp;The laboratory should check whether the PT report gives an explanation for the unsatisfactory performance. If no reason is provided, a stepwise approach is preferable to maximize the chances of determining the root cause of the problem. This approach is described in Annex B of the Eurachem Guide [1].<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_How_to_investigate_poor_performance_in_proficiency_testing_Annex_B_be140d5b39.jpg" alt="Eurachem: How to investigate poor performance in proficiency testing - Annex B" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_How_to_investigate_poor_performance_in_proficiency_testing_Annex_B_be140d5b39.jpg 153w," sizes="100vw" width="726" height="740">The investigation should consist of the following steps and involve the personnel that performed the analysis and where approporiate, also involve the laboratory management:&nbsp;<ol><li>Analyse the raw data, internal quality control data, any trend from previous PT rounds and the overall performance of the participants in that round;&nbsp;</li><li>After investigation is complete, make a plan for corrective action and consider implications for previous test results;&nbsp;</li><li>Execute and record the corrective action(s);&nbsp;</li><li>Check whether the corrective action(s) was effective.&nbsp;</li></ol><h4>Causes for poor performance&nbsp;</h4>The causes of poor performance can be grouped into three categories:&nbsp;<ol><li>Clerical errors are not directly linked to the laboratory’s technical competence, but can underline that the laboratory may have a potential problem when reporting results to its customers. Clerical errors can include transcription errors, mislabelling, incorrect units and decimal point errors. Identifying them is an important first step of an investigation. If such errors are a regular cause of poor performance, the investigation should focus on the related aspects of the quality management system.&nbsp;</li><li>Technical problems can occur at any step of the analytical procedure. If the investigation does not enable the laboratory to identify the root cause, it may be necessary to review the method validation.&nbsp;</li><li>Problems related to the PT scheme. Poor performance could also be due to the PT scheme not being entirely appropriate. The Eurachem Guide [1] provides information on selecting an appropriate PT scheme. In other cases, a problem may have occurred with the PT items. The laboratory is encouraged to discuss its findings with the PT provider.&nbsp;</li></ol>The “Fishbone diagram” or “5 Whys” are useful tools to investigate the root cause of a problem.<h4>Case studies&nbsp;</h4><h5>Example 1</h5>A medical laboratory has provided results in a PT scheme for tumor markers in serum with a 20 % deviation from the assigned value, although the daily internal controls performed well. The laboratory investigates the process and discovers the mistake was due to an incorrect unit conversion factor being introduced for PT results when the IT system was last updated. Since patient results are reported in a different unit than the one used by the PT provider no patient results were affected.&nbsp;<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_How_to_investigate_poor_performance_in_proficiency_testing_0df20b3875.jpg" alt="Eurachem: How to investigate poor performance in proficiency testing" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_How_to_investigate_poor_performance_in_proficiency_testing_0df20b3875.jpg 245w," sizes="100vw" width="1539" height="815"><h5>Example 2</h5>A laboratory performing food and feed analyses obtained poor performance scores on Listeria monocytogenes enumeration, because the number of microorganisms found was underestimated. Laboratory investigations showed an issue in incubation time and temperature applied by the analyst. The laboratory found that the analyst used an out-of-date procedure.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_How_to_investigate_poor_performance_in_proficiency_testing_2_4e56101bbb.jpg" alt="Eurachem: How to investigate poor performance in proficiency testing" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_How_to_investigate_poor_performance_in_proficiency_testing_2_4e56101bbb.jpg 245w," sizes="100vw" width="1185" height="526">

How to investigate poor performance in proficiency testing

ISC 2026 Keynote Lectures

Article

Events

Academy

Scientists

Toxicology

Science and research

A unique company dedicated to serving science helping our customers drive productivity and accelerate results. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.

Thermo Fisher Scientific

Eurachem is a European network promoting international traceability of chemical measurements and good analytical practice. It provides expert guidance, supports method validation, uncertainty evaluation, proficiency testing, and facilitates discussion on technical and policy issues in analytical quality.

Eurachem

The International Symposium on Chromatography (ISC) represents the oldest conference series focussing on separation science. ISC symposia have been organised since 1956 in each even year. ISC is internationally recognised as one of the premier meeting series for discussion of all modes of chromatography and separation science with a broad coverage of techniques and applications.

International Symposium on Chromatography - (ISC)

The Analytical Scientist

Agilent Technologies

Technology Networks

Bruker

SelectScience

Shimadzu Corporation

<ul>
<li>Discuss what GC-MS/MS is and what applicaitons it is used for (Dioxins, POPs, etc.)
</li>
<li>Transition into an overview of APGC as a solution
</li>
<li>Discuss challenges or limitations of the current GC/MS/MS technology
</li>
<li>Share why using nitrogen as a carrier gas for GC/MS/MS analysis is optimal
</li>
</ul>
Webinar Learning Objectives:
<ul>
<li>Understanding GC-MS/MS and Its Applications:- Discuss the principles of gas chromatography-mass spectrometry (GC-MS/MS) and its role in analytical chemistry.- Explore specific applications of GC-MS/MS, including its use in detecting dioxins, persistent organic pollutants (POPs), and other environmental contaminants.
</li>
<li>Introduction to APGC (Atmospheric Pressure Gas Chromatography):-. Provide an overview of Atmospheric Pressure Gas Chromatography (APGC) as an alternative solution to traditional GC-MS/MS.- Highlight the advantages and unique features of APGC, such as improved sensitivity, reduced matrix effects, and enhanced selectivity.
</li>
<li>Challenges and Innovations in GC-MS/MS Technology:- Identify the current challenges and limitations faced by GC-MS/MS technology.- Discuss recent innovations and advancements aimed at overcoming these challenges.- Emphasize the importance of using nitrogen as a carrier gas for GC-MS/MS analysis, considering its inertness, availability, and compatibility with various detectors.
</li>
</ul>
<blockquote>
Prtesenter: Frank Dorman (Senior Principal Market Development Mgr, Waters Corporation)
</blockquote>
<blockquote>
Frank Dorman is currently Senior Principal Market Development Manager for Waters focusing on their global environmental business and, concurrently, a Resident Scholar in the Chemistry Department at Dartmouth College in Hanover, NH where he is active in teaching analytical chemistry to undergraduates and graduate students.
</blockquote>
<blockquote>
In his role at Waters, Frank manages the research-focused environmental market, external collaborations, and interfaces with R&amp;D for new product development. Prior to this, Frank was an Associate Professor in the Department of Biochemistry and Molecular Biology (BMB) sat Penn State University in University Park, PA. At Penn State, Frank served as a member of the Graduate Faculty in: Biochemistry, Microbiology and Molecular Biology (BMMB), Chemistry (CHEM), Biogeochemistry (BGC) and the Forensic Science Program (FRNSC) and the Center for Molecular Toxicology and Carcinogenesis. Franks scientific interests are in gas and liquid chromatography and fundamental characterization, instrumentation and column development, as well as mass spectrometry and atomic spectroscopy as applied to trace analysis in complex sample matrices.
</blockquote>
<blockquote>
Presenter: Sarah Dowd (Principal Mass Spectrometry Applications Specialist, Waters Corporation)
</blockquote>
<blockquote>
Sarah Dowd joined Waters as a mass spectrometry application specialist in 2015 after earning her PhD in analytical chemistry from the University of Illinois at Urbana Champaign.
</blockquote>
<blockquote>
In her eight years at Waters in the Americas application lab, Sarah has collaborated with many customers looking to expand the MS capabilities of their laboratories with Water&#39;s instruments and software. Specializing in analyses in food, environmental, and polymeric materials characterization, she has done extensive work looking at environmental contaminants with tandem quadrupole and high resolution mass spectrometers.
</blockquote>
<blockquote>
One of the hot topics for the past couple of years is the analysis of per- and polyfluoroalkyl substances (PFAS) and Sarah has collaborated with customers and other scientists within Waters to guide the next phase of PFAS testing with Waters mass spectrometry systems.
</blockquote>

Waters Corporation: APGC Roundtable: Unveiling the Pathways of GC-MS/MS Evolution

APGC Roundtable: Unveiling the Pathways of GC-MS/MS Evolution

Discuss what GC-MS/MS is and what applicaitons it is used for (Dioxins, POPs, etc.)

APGC Roundtable: Unveiling the Pathways of GC-MS/MS Evo

Join us for an insightful webinar where we will explore the critical aspects of differentiating good from bad data and how this distinction can significantly influence your results. From screening to quantification, discover the value of targeted data analysis workflows using non-targeted data with our innovative software and hardware.Find by Formula algorithm. Learn to identify the most suitable MS/MS approach for your experiments, initiate quantitation for your compounds of interest, and incorporate retention times (RTs) and MS/MS spectra into a custom database and library.This session is designed to enhance your understanding and application of Q-TOF data analysis, ensuring robust and reliable outcomes.<blockquote>Presenter: Hannah Florance (Agilent Technologies)Hannah has had multiple roles in the life sciences, starting as a protein chemist, before moving into proteomics and then metabolomics. A major part of her time working in academia involved running LC and GCMS core facilities supporting projects ranging from synthetic biology to cancer research. She is currently an LCMS applications specialist for Agilent. Presenter: Stefan Schaebler (Application Specialist LC/MS, Agilent Technologies)Stefan completed his PhD in Biology, specializing in LC-MS-based lipidomics and metabolomics. Following his doctoral studies, he joined Agilent Technologies as an LC/MS Application Specialist. In this role, Stefan focuses on small molecule applications using LC-QTOF, with a strong emphasis on software tools and data interpretation.</blockquote>

Agilent Technologies: MassHunter Masterclass Months

MassHunter Qual – The Solid Pillar in Q-TOF Data Analysis

We will explore the critical aspects of differentiating good from bad data and how this distinction can significantly influence your results.

Join our upcoming webinar on the MassHunter Quant Screener Tool to discover how to harness the power of quantitative analysis for effective screening and identification of potential suspect compounds.This session will provide in-depth guidance on creating methods from PCDL databases, evaluating result parameters, and generating straightforward summary reports. Additionally, learn how retention time (RT) prediction can enhance your screening process by significantly accelerating and simplifying large database searches.Don’t miss this opportunity to elevate your analytical capabilities!<blockquote>Presenter: &nbsp;Jonathan Spencer (Application Specialist, Agilent Technologies)Jonathan studied BSc Natural Sciences at the University of Nottingham and later went on to Sheffield Hallam University to study a MSc in Forensic Science.Following graduation, he spent 2 years as a Confirmatory Analyst in an anti-doping and forensic toxicology lab, before joining Agilent as an LC/MS Applications Scientist. At Agilent, he focuses on small molecule applications using LC/TQ and LC/Q-TOF in fields of like food, forensic and environmental analysis.</blockquote>

MassHunter Quant Screener Tool

Discover how to harness the power of quantitative analysis for effective screening and identification of potential suspect compounds. 

<div>To unravel the functions of the vast universe of small molecules in human biology it is essential to first detect and quantify these molecules—a task carried out by the field of metabolomics. In traditional liquid chromatography-mass spectrometry (LC-MS)-based metabolomics, quantitative analysis is divided across two categories: relative or absolute.&nbsp;&nbsp;&nbsp;In this webinar we will explore the importance of metabolomics in disease research, and the challenges associated with LC-MS based metabolomics studies. We will also introduce Pyxis, a scalable, machine learning-based approach to absolute quantitation of metabolites across various matrices, and potential applications in research and the clinic.&nbsp;Learning Objectives<ul><li>The application of quantitation in understanding metabolite functions in biological systems.</li><li>The experimental requirements of absolute and relative quantitation of metabolites along with their benefits and limitations.</li><li>Introduction of Pyxis, a method that enables scalable absolute quantitation of metabolites without relying on isotopically labeled standards.</li></ul><blockquote>Presenter: Naama Kanarek, PhD (Assistant Professor, Pathology Department at Boston Children’s Hospital and Harvard Medical School)A native of Jerusalem, Israel, Dr. Naama Kanarek trained at the Hebrew University, where she earned a BSc in medical science, an MSc in proteomics and microbiology, and a PhD in immunology and cancer research (including one year at Columbia University Medical Center, NY). Dr. Kanarek’s postdoctoral research was performed under the supervision of Prof. David M. Sabatini at MIT’s Whitehead Institute.Dr. Kanarek is the recipient of a number of awards and honors, including the Margaret and Herman Sokol Postdoctoral Award, the Leukemia and Lymphoma Society New Idea Award, the Hebrew University Women in Science Postdoctoral Award, the Weizmann Institute Postdoctoral Award for Advancing Women in Science and a Revson Fellow of that program, and the James Sivarsten Prize in Pediatric Cancer Research. Her postdoctoral work was supported by fellowships from the American Association for Cancer Research and the European Molecular Biology Organization.Dr. Kanarek’s laboratory is interested in folate metabolism, and the metabolic adaptations of cells as they move around and migrate to new sites. They apply genetic perturbations, biochemical assays, molecular biology, functional genomic screens, and metabolite profiling by mass spectrometry in cell-culture systems and in vivo. They study basic folate biology including folate metabolism, folate-related signal transduction, the oncogenic role of folate and folate homeostasis in normal physiology and pathological conditions.Presenter: Jennifer M. Campbell, PhD (Chief Scientific Officer, Matterworks, Inc.)Jennifer M. Campbell, PhD is currently Chief Scientific Officer at Matterworks, a multidisciplinary startup focused on using the power of deep learning on raw mass spectrometric data. Their first product, Pyxis, enables scalable quantitative metabolomics through the use of AI. Prior to Matterworks, Dr. Campbell worked at Novartis Institutes of Biomedical Research, heading up MS and separations within the Cambridge (MA) chemistry department. Dr. Campbell served as technical lead of NeoBase2, an FDA 510K approved assay for newborn screening at Perkin Elmer and Director of Proteomics at BG Medicine. Her career started in instrument development - she obtained her PhD, which focused on the development of a linear ion trap-TOFMS at the University of British Columbia under Don Douglas and she worked for eight years at Applied Biosystems, aiding in the development of all aspects of the MALDI TOF/TOF product line (4700, 4800, and 5800). She has authored numerous papers, patents, and book chapters.</blockquote></div>

The Analytical Scientist: A scalable approach to absolute quantitation in metabolomics

A scalable approach to absolute quantitation in metabolomics

We will explore the importance of metabolomics in disease research, and the challenges associated with LC-MS based metabolomics studies.

Hear about the latest advancements in translational proteomics and metabolomics. From the molecular mechanisms of disease pathology to the latest technological developments in diagnostics and treatment.<h5>Key Learning Objectives:</h5><ul><li>Spatial proteomics to assess health and diseases</li><li>Absolute quantitation of human proteins</li><li>The latest innovations in proteomics and metabolomics instrumentation and data analysis</li><li>Biomarker-guided precision medicine</li></ul><h4>Day 2 – October 31</h4><h5>15:00 – 15:50 GMT: A Novel Strategy for the Absolute Quantification of Human Proteins</h5><ul><li>Christoph Borchers, PhD (McGill University)</li></ul><h5>15:50 – 15:55 GMT: Networking Break</h5><h5>15:55 – 16:15 GMT: From Single Cells to the Metaproteome: Latest Developments in timsTOF Technology for Proteomics</h5><ul><li>Matt Willetts, PhD (Bruker)</li></ul><h5>16:15 – 16:20 GMT: Networking Break</h5><h5>16:20 – 17:10 GMT: Single-Cell Chromatin Proteomics to Investigate the Biology of Exceptional Longevity</h5><ul><li>Simone Sidoli, PhD (Albert Einstein College of Medicine)</li></ul><h5>17:10 – 17:15 GMT: Networking Break</h5><h5>17:15 – 17:35 GMT: Optimizing Metabolomics Workflows: From Sample Preparation to Multi-omics Integration</h5><ul><li>Hagen Magnus Gegner, PhD (CTC Analytics)</li></ul><h5>17:35 – 17:40 GMT: Networking Break</h5><h5>17:40 – 18:10 GMT: Analyzing Metabolic Responses to a Standardized Meal Challenge Using Exhaled Breath</h5><ul><li>Matteo Tardelli, PhD (Owlstone Medical)</li></ul><h5>18:10 GMT: Event Close</h5><h5>Who Should Attend:</h5><ul><li>Scientists and researchers seeking to expand their knowledge</li><li>Pharmaceutical and biotech professionals driving drug development</li><li>Clinicians looking to improve patient care</li><li>Academicians exploring new research avenues</li><li>Graduate students and postdoctoral fellows building their careers</li></ul><blockquote>Presenter: Mathias Uhlén, PhD (Professor, KTH - Royal Institute of Technology)Presenter:&nbsp;Christoph Borchers, PhD (Professor, McGill University)Presenter:&nbsp;Janne Lehtiö, PhD (Professor, Karolinska Institutet)Presenter:&nbsp;Crystal Montoya (Senior Marketing Product Manager, Miltenyi Biotec)Presenter:&nbsp;Kari Basso, PhD (Director of Mass Spectrometry Research and Education, University of Florida)Presenter:&nbsp;Fabian Coscia, PhD (Group Leader, Max Delbrück Center)Presenter:&nbsp;Simone Sidoli, PhD (Assistant Professor, Albert Einstein College of Medicine)Presenter:&nbsp;Hagen Magnus Gegner, PhD (Content and Digital Marketing, CTC Analytics)Presenter:&nbsp;Matt Willetts, PhD (Proteomics Applications Manager, Bruker Daltonics)Presenter:&nbsp;Matteo Tardelli, PhD (Senior Biomarker Scientist, Owlstone Medical)Presenter:&nbsp;Aaron Gajadhar, PhD (Director, Strategic Applications, Seer)Presenter:&nbsp;Gary Siuzdak, PhD (Professor and Senior Director, Scripps Research Institute)</blockquote>

Technology Networks: Advances in Proteomics & Metabolomics 2024

Advances in Proteomics & Metabolomics 2024 (Day 2)

Hear about the latest advancements in translational proteomics and metabolomics. 

Advances in Proteomics & Metabolomics 2024  (Day 1)

<div><div><div>Targeted protein degradation (TPD) is a powerful therapeutic modality to eliminate disease-causing proteins that are resistant to conventional drugs. In this webinar, we present a high-throughput scalable proteomics approach that utilizes label-free, single-shot dia-PASEF® mass spectrometry to identify novel degrader targets on a large scale with unmatched coverage, accuracy, and speed. A combination of DIA-NN software and advanced statistical tools guarantees rapid, automated analysis of large proteomics datasets with highest precision of quantification, data completeness and sensitivity. A slice-PASEF-based global ubiquitinomics approach will be presented that verifies degrader-induced modifications with an unprecedented depth of 50,000 ubiquitination sites. In addition, a data analysis suite designed for user-friendly evaluation and in-depth meta-analysis will be shown, making proteomics data easily accessible for target identification, SAR optimization, library expansion and strategic drug discovery decisions.</div></div></div><div><div><div>About NEOsphere Biotechnologies:NEOsphere Biotechnologies is a leading partner in TPD (Targeted Protein Degradation) proteomics, collaborating with pharmaceutical and biotechnology companies to advance drug discovery and develop innovative degrader pipelines. The platform combines cutting-edge mass spectrometry technologies with advanced biostatistical data analysis, enabling high-throughput proteomic screening of entire degrader libraries and mechanistic target validation, including global ubiquitinomics. NEOsphere Biotechnologies offers unmatched sensitivity, precision, and turnaround times, facilitating the large-scale identification of novel degrader targets and the systematic exploration of previously undruggable therapeutic targets. You will learn about:&nbsp;<ul><li>A high-throughput proteomics approach that utilizes label-free, single-shot dia-PASEF to identify novel degrader targets on a large scale with unmatched coverage, accuracy, and speed</li><li>The verification of degrader-induced modifications using an optimized acquisition strategy based on slice-PASEF-based global ubiquitinomics</li><li>The benefit of combining the capabilities of a timsTOF HT and a timsTOF Ultra 2</li></ul><blockquote>Presenter: Uli Ohmayer, Ph.D. (Head of Mass Spectrometry and Founder, NEOsphere Biotechnologies GmbH, Munich, Germany)</blockquote></div></div></div>

Bruker: Unlock the therapeutic potential of targeted protein degradation with deep proteomic screening

Unlock the therapeutic potential of targeted protein degradation with deep proteomic screening

High-throughput scalable proteomics approach that utilizes label-free, single-shot dia-PASEF® mass spectrometry

Targeted protein degradation with deep proteomic screening

The complexity of biological systems and diseases, such as Alzheimer’s disease, necessitates spatial multiomics techniques to gain a holistic understanding of cell-cell interactions and communication. A singular approach to spatial multiomics is possible with MALDI Imaging, including label-free imaging of small molecules, lipids, drugs, and glycans. Additionally, with technology developed by AmberGen, Inc., photocleavable mass-tag (PCMT) conjugated affinity probes are available for antibodies, oligos, and lectins.Key Learning Objectives:<ul><li>Learn the spatial biology utility of MALDI Imaging</li><li>Understand multiomics workflows and the applications to disease-based research</li></ul>Who Should Attend:<ul><li>Researchers interested in multiomics brain analysis</li><li>Investigators researching Alzheimer’s disease</li></ul><blockquote>Presenter: Mark Lim, Ph.D. (Chief Scientific Officer and Executive VP, AmberGen Inc., Billerica, MA, USA)Mark Lim Ph.D. is the Chief Scientific Officer and Executive VP at AmberGen Inc. He has over 23 years’ experience in the biotechnology industry and has been awarded over 20 patents which underlie key technologies in the biotechnology industry, including in the fields of proteomics, genomics/transcriptomics, and diagnostics. His early work at AmberGen on photocleavable linkers and protein engineering contributed to the commercialization of a variety of novel reagents including PC-Biotin, PC-Phosphoramidites and fluorescent suppressor tRNAs. Dr. Lim now leads the application of these core AmberGen technologies to multiomic biomarker discovery and biomarker-driven diagnostics.Presenter: Kate Stumpo, Ph.D. (Senior Market Manager, Bruker Scientific, Billerica, MA, USA)Dr. Kate Stumpo is a Market Manager which entails messaging and marketing for MALDI Imaging. Dr. Stumpo completed her Ph.D. at Texas A&amp;M University, and is an expert in MALDI applications, including MALDI Imaging.</blockquote>

Bruker: Advancing understanding of Alzheimer’s disease using multiomics spatial biology

Advancing understanding of Alzheimer’s disease using multiomics spatial biology

Learn the spatial biology utility of MALDI Imaging. Understand multiomics workflows and the applications to disease-based research.

Understanding of Alzheimer’s with multiomics spatial biology

In today’s fast-paced research environment, optimizing lab workflows is crucial to maintaining productivity and ensuring high-quality results. Sample preparation is a critical step in chromatography and mass spectrometry, yet it often involves time-consuming and error-prone manual processes.Join us for an exclusive webinar with Dr. Jens Lättig, Senior Scientist at Tecan and Dr. Cassandra Rusher, European Technical Support Specialist at Eprep, where they’ll reveal how the Resolvex® Prep revolutionizes sample preparation for chromatography and mass spectrometry.Key learning objectives:<ul><li>Slash prep time: Discover how you can reduce your setup to just 5–15 minutes, freeing you to focus on critical tasks while Resolvex® Prep works autonomously.</li><li>Enhance accuracy: Learn how analytical syringes and specialized tools deliver consistent, reliable results – minimizing human error.</li><li>Achieve consistency: Find out how you can achieve repeatable results across various sample types and workflows, streamlining your processes.</li><li>Unlock versatility: Explore Resolvex® Prep’s built-in wash station, RFID deck scan, and seamless sample transfer, all designed to meet your research needs.</li></ul>Who should attend?<ul><li>Laboratory scientists and managers from analytical laboratories in: pharma, biopharma, biotech, the food industry, the environmental sector, agriculture, drug screening, proteomics, and metabolomics.</li></ul>Certificate of attendanceAll webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.<blockquote>Presenter: Jens Lattig, PhD (Sales Development Manager Proteomics &amp; MS Sample Prep, Tecan)Dr. Jens Lättig is a Sales Development Manager Proteomics &amp; MS Sample Preparation at Tecan. He has a PhD in biochemistry, and has worked in drug research projects in Germany and France. At Tecan, he is responsible for the Resolvex™ instruments and consumables portfolio in Europe.Presenter: Cassandra Rusher, PhD (European Technical Support Specialist, Eprep)Dr. Cassandra Rusher is a technical support specialist for the Resolvex Prep. at Eprep. She has a PhD in chemistry and a background specializing in chromatography including sample preparation. Her previous roles have included technical support and product management in the analytical chromatography sector. Her focus now is on supporting the automation of sample preparation methods across a range of industries that are utilizing analytical chromatography techniques.Moderator: Carrie Haslam (Associate Editor, SelectScience)</blockquote>

SelectScience: Efficient sample prep for expert mass spectrometry and chromatography

Efficient sample prep for expert mass spectrometry and chromatography

Join us for a webinar where we will reveal how the Resolvex® Prep revolutionizes sample preparation for chromatography and mass spectrometry.

Efficient sample prep for MS and chromatography

Are you ready to transform your pharmaceutical operations? Don’t miss our exclusive session on Shimadzu Digital Classrooms and begin your journey towards Pharma digital transformation (DX). Discover how Shimadzu’s pioneering AI technologies and digital solutions are ushering in a new era of pharma innovation.In this informative session, explore how Shimadzu is reshaping the drug development landscape. Learn how our innovative tools effectively streamline workflows, enhance lab efficiency, and maintain strict compliance with regulatory standards.Whether you’re a forward-thinking researcher, a quality assurance professional, or a strategic decision-maker, this session is your gateway to mastering AI and digital transformation. Equip yourself with the expertise and resources to stay ahead in the industry.This is an opportunity not to be missed – Register Now!Learning Objectives:&nbsp;<ul><li>Understand how to stay conforming to the Pharma regulations and USP 621 changes with Shimadzu Living Laboratory</li><li>Explore Shimadzu AI and Automation to elevate your lab workflows effectively</li><li>Learn about the AI features of Shimadzu Ai-series and Nexera series</li><li>Gain insights into efficient quality control strategies with Shimadzu Data Management and Software</li></ul><blockquote>Presenter: Liw Wan Tung (Assistant Market Manager (Pharma) Shimadzu (Asia Pacific) Pte Ltd)Wan Tung is the LC Product Manager and Pharmaceutical market in-charge at Shimadzu Asia Pacific Pte Ltd. She is the LC expert with more than 15 years of working experience in analytical science, specializing in method development of various LC and LCMS applications. In 2012, she joined Shimadzu to develop end-to-end workflow solutions for the customers. She has supported a multitude of applications from impurity analysis to drug discovery and biopharmaceutical applications. Prior to joining Shimadzu, Wan Tung started her professional career as a QAQC chemist in Pharmaceutical multinational company. Wan Tung earned her bachelor’s honour's degree in chemistry back in 2009.Presenter: Kanimozhi Sivarajan (Informatics Manager Shimadzu (Asia Pacific) Pte Ltd)Dr. Kani is having 10 years of experince in Laboratory Management and Informatics &nbsp;Systems. She is serving as Informatics Manager at Shimadzu Asia Pacific, Singapore, &nbsp;providing Lab Informatics Solutions such as LabSolutions CS, LIMS and other QMS applications. She is supporting customers from various segments on implementing laboratory automation and responsible for providing consultation on streamlining Lab Workflows, Regulatory Compliance requirements for Electronic Data Management and Lab Practices/Analysis.&nbsp;</blockquote>

Shimadzu:  Realizing Pharma DX: Discover Shimadzu’s AI-Driven Solutions And Automation

 Realizing Pharma DX: Discover Shimadzu’s AI-Driven Solutions And Automation

Discover how Shimadzu’s pioneering AI technologies and digital solutions are ushering in a new era of pharma innovation.

Pharma DX: Shimadzu’s AI-Driven Solutions And Automation

This presentation discusses the work being done to understand how drugs work and how they can be repurposed for new indications. Prof. Küster’s lab uses various technologies and methods, such as sample preparation, mass spectrometry, and informatics, to study the proteome and fosso-proteome of cancer patients.The goal is to find the right drug for the right person by understanding what is going wrong in the patient and what the drugs can do. By studying drug-protein interactions and pathway engagement in a dose-dependent fashion, this research aims to make better treatment recommendations. The lab has developed a technology platform that allows for the systematic profiling of kinase inhibitors and the measurement of proteome expression changes in response to drugs.This information can help prioritize biological effects and facilitate drug repurposing. This presentation highlights the importance of studying proteins in understanding drug mechanisms of action and identifying potential targets for cancer treatment.Learning points:<ul><li>Importance of Repurposing Drugs &nbsp;</li><li>Role of Proteomics in Precision Oncology &nbsp;</li><li>Dose-Dependent Analysis &nbsp;</li></ul><blockquote>Presenter: Prof. Bernhard Küster (Technical University Munich)Bernhard Küster holds a chemistry degree from Cologne, a PhD in Biochemistry from Oxford and did a PostDoc at the EMBL in Heidelberg and the University of Southern Denmark. After seven years as Vice President Analytical Sciences and Informatics at Cellzome (now GSK), he became.​Full Professor of Proteomics at the TU Munich in 2007. He also directs the Bavarian Biomolecular Mass Spec-trometry Center and the Clinical Mass Spectrometry Center Munich.​Bernhard’s research focuses on proteomics and its application to chemical and cancer biology. He is interested in understanding how cancer drugs actually work and has received an ERC Advanced Grant in 2019 aiming to integrate proteomics into precision medicine. Bernhard has received several awards, including from HUPO for a draft human proteome and his contri-butions to chemical proteomics. Bernhard is a member of the German National Academy of Science, Leopoldina and has co-founded two start-up companies that operate in the area of proteomics and artificial intelligence.</blockquote>

Thermo Fisher Scientific: Understanding drugs using proteomics

Understanding drugs using proteomics

This presentation highlights the importance of studying proteins to understand drug mechanisms and identify potential targets for cancer treatment

LCMS webinars focusing on LC/MS - page 47